# Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

Study · id `cardio:ct-nct04968184` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04968184](<https://clinicaltrials.gov/study/NCT04968184>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT04968184

Browse, organ or system: Blood vessels; Kidneys  
Browse, condition area: High blood pressure; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 666 participants.

## Technical summary

Registry record NCT04968184. Randomized; quadruple masking; primary purpose treatment. Start 2021-11-05 (actual); primary completion 2024-01-30 (actual). Results posted on 2026-11-04.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 666 participants (enrolled count; ClinicalTrials.gov record NCT04968184, source copy `cardio:ctgov-nct04968184-2026-11-04`, retrieved 2026-11-18)
- Started: 2021-11-05 (actual) (ClinicalTrials.gov record NCT04968184, source copy `cardio:ctgov-nct04968184-2026-11-04`, retrieved 2026-11-18)
- Primary completion: 2024-01-30 (actual) (ClinicalTrials.gov record NCT04968184, source copy `cardio:ctgov-nct04968184-2026-11-04`, retrieved 2026-11-18)
- Completion: 2024-07-10 (actual) (ClinicalTrials.gov record NCT04968184, source copy `cardio:ctgov-nct04968184-2026-11-04`, retrieved 2026-11-18)
- Results first posted: 2026-11-04 (ClinicalTrials.gov record NCT04968184, source copy `cardio:ctgov-nct04968184-2026-11-04`, retrieved 2026-11-18)
- Countries: United States; Australia; Bosnia & Herzegovina; Bulgaria; Canada; China; Croatia; Czechia; Georgia; Germany; Hong Kong SAR China; Hungary; Israel; Latvia; Lithuania; Malaysia; Poland; Serbia; South Africa; South Korea; Spain; Taiwan (ClinicalTrials.gov record NCT04968184, source copy `cardio:ctgov-nct04968184-2026-11-04`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04968184-2026-11-04`, retrieved 2026-11-18)

## The registry's words

- Brief title: Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)
- Acronym: Clarion-CKD
- Condition: Chronic Kidney Diseases
- Intervention (Drug): Placebo
- Intervention (Drug): KBP-5074
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY
- Collaborator: KBP Biosciences
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: fb589957dfc67f37e2075915b49152790a38745d99d847f9a15bcb1d8f1a1e8e
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
